Cargando…

A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients

BACKGROUND: Adrenal androgens play an important role in the development of castration-resistant prostate cancer therapeutics. The effect of gonadotropin-releasing hormone (GnRH) antagonists on adrenal androgens has not been studied sufficiently. We measured testicular and adrenal androgen levels in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyazawa, Yoshiyuki, Sekine, Yoshitaka, Syuto, Takahiro, Nomura, Masashi, Koike, Hidekazu, Matsui, Hiroshi, Shibata, Yasuhiro, Ito, Kazuto, Suzuki, Kazuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575925/ https://www.ncbi.nlm.nih.gov/pubmed/28851333 http://dx.doi.org/10.1186/s12894-017-0261-z

Ejemplares similares

Effects of a luteinizing hormone-releasing hormone agonist on cognitive, sexual, and hormonal functions in patients with prostate cancer: relationship with testicular and adrenal androgen levels
por: Okamoto, Kohei, et al.
Publicado: (2015)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2015)

Presepsin as a predictor of septic shock in patients with urinary tract infection
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Androgen receptor coactivator p120 subtype β is highly expressed in prostate cancer
por: Muramatsu, Kazumichi, et al.
Publicado: (2013)

Chlormadinone acetate is effective for hot flush during androgen deprivation therapy
por: Koike, Hidekazu, et al.
Publicado: (2013)

Chronic expanding hematoma in the retroperitoneal space: a case report
por: Syuto, Takahiro, et al.
Publicado: (2013)

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2022)

Simple method for preventing inguinal hernias after radical retropubic prostatectomy
por: Koike, Hidekazu, et al.
Publicado: (2013)

Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins
por: Furuya, Yosuke, et al.
Publicado: (2016)

Retroperitoneal urothelial carcinoma arising after bladder diverticulectomy: a case report
por: Ohtsu, Akira, et al.
Publicado: (2023)

Changing pattern of gonadotropins in a patient with an adrenal‐androgen secreting tumor
por: Marcondes, José Antonio Miguel, et al.
Publicado: (2011)

Ovarian and Adrenal Androgens and Their Link to High Human Chorionic Gonadotropin Levels: A Prospective Controlled Study
por: Rodríguez-Gutiérrez, René, et al.
Publicado: (2014)

Crinecerfont, a CRF(1) Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia
por: Newfield, Ron S, et al.
Publicado: (2023)

A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2021)

Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis
por: Kunath, Frank, et al.
Publicado: (2015)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles
por: Jain, Shikha, et al.
Publicado: (2016)

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
por: Ueda, Takashi, et al.
Publicado: (2021)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?
por: Rzewuska, Anna Maria, et al.
Publicado: (2023)

Role of circulating tumor cell clusters in patients with metastatic hormone-sensitive prostate cancer receiving a gonadotropin-releasing hormone antagonist: A pilot study
por: Kohada, Yuki, et al.
Publicado: (2023)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Original delayed-start ovarian stimulation protocol with a gonadotropin-releasing hormone antagonist, medroxyprogesterone acetate, and high-dose gonadotropin for poor responders and patients with poor-quality embryos
por: Takeuchi, Kazuhiro, et al.
Publicado: (2023)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Early gonadotropin-releasing hormone antagonist start improves follicular synchronization and pregnancy outcome as compared to the conventional antagonist protocol
por: Park, Chan Woo, et al.
Publicado: (2014)

Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
por: Park, Sumi, et al.
Publicado: (2014)

Small molecule piperazinyl-benzimidazole antagonists of the gonadotropin-releasing hormone (GnRH) receptor
por: Fjellaksel, Richard, et al.
Publicado: (2017)

The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome
por: Chappell, Neil, et al.
Publicado: (2017)

Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
por: Liu, Yi-Fu, et al.
Publicado: (2021)

Comparison of Two Regimens of Gonadotropin-releasing Hormone Antagonists in Clomiphene-gonadotropin Induced Controlled Ovulation and Intrauterine Insemination Cycles: Randomized Controlled Study
por: Karthik, Sajja Devendra Siva, et al.
Publicado: (2018)

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL
por: Kashiwabara, Takeshi, et al.
Publicado: (2018)

Luteal estradiol supplementation in gonadotropin-releasing hormone antagonist cycles for infertile patients in vitro fertilization
por: Kwon, Su-Kyoung, et al.
Publicado: (2013)

Comparative proteomics reveal negative effects of gonadotropin-releasing hormone agonist and antagonist on human endometrium
por: Chen, Qian, et al.
Publicado: (2019)

Editorial Comment to Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
por: Kawahara, Takashi
Publicado: (2020)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

Pretreatment with gonadotropin-releasing hormone antagonist protects against chemotherapy-induced testicular damage ‘in mice
por: Levi, Mattan, et al.
Publicado: (2022)

OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia
por: Auchus, Richard, et al.
Publicado: (2022)

Dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles
por: Albeitawi, Soha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vo1a1eqd5hajomsh9gsol9g0ro